Conference: 4th International Conference In Prophetic Medicine Research
Keywords: Nanoparticles ellagic acid, cisplatin, hepatotoxicity
Background and Objective
Ellagic acid (ELL) is a phenolic constituent of natural sources with antioxidant and anti-inflammatory activities. The ELL has a low bioavailability,therefore a nanoparticles (NP ELL) was formulated to
determine whether NP ELLcould alleviate cisplatin (CISP)-induced hepatotoxicity in comparison to a high dose of regular ELL.
Materials and Methods
The NP ELL was prepared using an emulsion solvent diffusion technique. Hepatotoxicity was induced in rats using CISP (7.5 mg kgG). 1Rats were pre-treated with either 10 ELL (10 mg kgG) 1 NP ELL (1 mg kgG) or 2 NP ELL (2 mg kgG)
All ELL regimens significantly decreased CISP-induced increases in liver enzymes, MDA, NO, TNF-”, NFkB and BAX. Additionally, all significantly restored hepatic GSH, GPx, CAT and Bcl-2. Ratʼs liver showed no injury in all ELL pretreated groups. Importantly, NP ELL did not inhibit the cytotoxic effect CISP against HCT116 cell lines.
The NP ELL has improved bio-availability and protected against CISP induced hepatotoxicity. This provides an encouraging way of ameliorating the bio-availability of ELL while sustaining its desirable therapeutic effects.